Gland Pharma Receives USFDA Approval for Generic Sugammadex Injection
Gland Pharma has received USFDA approval for its generic Sugammadex Injection in 200 mg and 500 mg single-dose vials. The drug reverses neuromuscular blockade caused by rocuronium and vecuronium during surgery and is bioequivalent to Merck's BRIDION Injection. The product had US sales of approximately $1.6 billion in the year ending April 2026. Gland Pharma has commercially launched the product in the US and reported significant profit and sales growth in its recent financial quarter.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 41/100.
Outlets measured: thehindu, businessstandard, economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 29 Jul, 06:58 am. Other outlets followed.